๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Multiple Myeloma (MM)
Clinical trial register · China

Multiple Myeloma (MM) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 6 Beijing 6 Wuhan 3 Nanjing 2 Xuzhou 2
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin6 Beijing6 Wuhan3 Nanjing2 Xuzhou2
All 14 locations
Target enrolment
to

Multiple Myeloma (MM) trials in China

17 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
NCT07585760Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
26
Tianjin
2026-09-10
Not yet open
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
NCT07811986Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-09-01
Not yet open
Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
NCT07687004Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2026-08-01
Not yet open
Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07628595Multiple Myeloma (MM)
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
19
Nanjing
2026-07-01
Not yet open
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
NCT07660939Plasma Cell Disorders, Multiple Myeloma (MM)
Peking University First Hospital
Phase 1
50
Beijing
2026-06-25
Not yet open
BR101 in Patients With Relapsed/Refractory Multiple Myeloma
NCT07537049Multiple Myeloma (MM)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
10
Beijing
2026-04-30
Not yet open
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
NCT07539233Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
24
Tianjin
2026-04-15
Recruiting
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
NCT07429721Multiple Myeloma (MM)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
24
Wuhan
2026-03-03
Not yet open
Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
NCT07353554Multiple Myeloma (MM)
Peking Union Medical College Hospital
Not applicable
30
Beijing
2026-02-01
Not yet open
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma๏ผˆLB2505-0001๏ผ‰
NCT07399444Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
38
Zhengzhou, Wuhan, Xuzhou, Nanchang, Beijing, Tianjin
2026-01-10
Recruiting
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
NCT07101705Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
40
Wuhan
2025-09-08
Not yet open
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
NCT07181239Multiple Myeloma (MM)
Keymed Biosciences Co.Ltd
Phase 3
280
Tianjin
2025-09
Not yet open
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
NCT07113496Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL), Multiple Myeloma (MM), Plasmablastic Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1
27
Nanjing
2025-08
Not yet open
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
NCT07034755Multiple Myeloma (MM), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Chimeric Antigen Receptor T-cell
The Affiliated Hospital of Xuzhou Medical University
Not applicable
20
Xuzhou
2025-07-01
Recruiting
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
NCT07085559Multiple Myeloma (MM), Plasma Cell Leukemia (PCL), AL Amyloidosis (AL)
Anhui Provincial Hospital
Phase EARLY_PHASE1
36
Hefei
2025-06-23
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/multiple-myeloma-mm

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies listing the condition Multiple Myeloma (MM).

How many Multiple Myeloma (MM) trials are recruiting in China?

6 of the 17 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 11 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Multiple Myeloma (MM)), 17 studies
PhaseStudiesRecruitingShare
Phase EARLY_PHASE16335.3%
Phase 14123.5%
Not applicable2011.8%
Phase 22111.8%
Phase 32111.8%
Phase 1/2105.9%

Most active sponsors

Lead sponsors with the most studies (Multiple Myeloma (MM))
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China51
The First Affiliated Hospital with Nanjing Medical University20
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology22
Anhui Provincial Hospital11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences10
Keymed Biosciences Co.Ltd10
Peking Union Medical College Hospital10
Peking University First Hospital10
Shanghai Henlius Biotech11
Sinocelltech Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.